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a b s t r a c t
Background: Little is known regarding the recognition of anxiety in children and young people (CYP) in
primary care. This study examined trends in the presentation, recognition and recording of anxiety and
of anxiolytic and hypnotic prescriptions for CYP in primary care.
Method: A population-based retrospective electronic cohort of individuals aged 6–18 years between
2003 and 2011 within the Secure Anonymised Information Linkage (SAIL) Databank primary care
database was created. Incidence rates were calculated using person years at risk (PYAR) as a denominator
accounting for deprivation, age and gender.
Results: We identiﬁed a cohort of 311,343 registered individuals providing a total of 1,546,489 person
years of follow up. The incidence of anxiety symptoms more than tripled over the study period
(Incidence Rate Ratio (IRR)¼3.55, 95% CI 2.65–4.77) whilst that of diagnosis has remained stable.
Anxiolytic/hypnotic prescriptions for the cohort as a whole did not change signiﬁcantly over time;
however there was a signiﬁcant increase in anxiolytic prescriptions for the 15–18 year age group (IRR
1.62, 95% CI 1.30–2.02).
Limitations: There was a lack of reliable information regarding other interventions available or received
at a primary, secondary or tertiary level such as psychological treatments.
Conclusions: There appears to be a preference over time for the recording of general symptoms over
diagnosis for anxiety in CYP. The increase in anxiolytic prescriptions for 15–18 year olds is discrepant
with current prescribing guidelines. Speciﬁc guidance is required for the assessment and management of
CYP presenting with anxiety to primary care, particularly older adolescents.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Mental health issues are of growing concern and a source of
controversy in children and young people (CYP) in the United
Kingdom (U.K). They are associated with signiﬁcant morbidity and
have been found to contribute to adverse life outcomes (such as
educational underachievement) and serious disruptions to CYP's
lives and those of their families (Patel et al., 2007). It is estimated
from Ofﬁce of National Statistics population survey data that, at
any one time, four per cent of CYP, have a clinically diagnosable or
relevant emotional disorder (anxiety or depression; Ofﬁce of
National Statistics, 2004). Anxiety disorders are thought to be
among the earliest psychiatric conditions to manifest with an
estimated median age of onset of 11 years (Kessler et al., 2005).
Earlier age of onset appears to be associated with greater severity
and poorer long term outcomes (Ramsawh et al., 2011). Concerns
are ampliﬁed by the persistence of childhood or adolescent mental
health issues into adulthood (Costello et al., 2006) where up to a
ﬁfth of the adult population may be affected by a common mental
disorder at any one time (McManus et al., 2009; Leray et al., 2011).
There are fears that we are medicalising unhappiness with
consequent over diagnosis and excessive treatment (Dowrick and
Frances, 2013). This is particularly relevant in CYP where there is a
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normal developmental range of anxiety-related phenomena (e.g.
stranger anxiety, fear of the dark, existential questioning) as they
develop cognitively and emotionally and engage with the world.
Signiﬁcant increases in the rates of psychotropic prescriptions in
CYP have been found in America (Olfson et al., 2002), Europe
(Steinhausen and Bisgaard, 2014) and the UK (Middleton et al.,
2001; Rani et al., 2008) over the past three decades. Such ﬁndings
contribute to concern over the medicalisation of normal human
experience, particularly following the release of the Diagnostic and
Statistical Manual of Mental Disorders 5 (DSM-5; American
Psychiatric Association, 2013). This revision has been heavily
criticised for pathologising normal human behaviour such as
eccentricity, loneliness and sadness (Watts, 2012), and for its
potential to cause excessive and inappropriate use of medication
in children (Gaughwin, 2014).
Access to services in primary care represents a key factor in the
management of CYP mental health issues. Research utilising
routinely collected data in primary care in the UK has identiﬁed
a fall in recorded diagnoses and rise in recorded symptoms of
depression alongside an increase in new antidepressant prescrip-
tions in both adults (Rait et al., 2009) and CYP (Wijaars et al.,
2012). Adult data suggests that this recording behaviour is being
applied to anxiety disorders (Walters et al., 2012); however there
are currently no such data available on CYP and little is known
regarding the use of anxiolytics and hypnotics in this population in
this setting. There are no speciﬁc National Institute of Clinical
Excellence (NICE) guidelines available for the management of
anxiety in CYP. There are NICE guidelines for anxiety (which relate
principally to adults; NICE, 2011), depression for CYP (which
includes mixed anxiety and depression; NICE, 2005) and for the
assessment and treatment of social anxiety disorder (NICE, 2013).
These all highlight some considerations for the management of
anxiety in CYP. Psychological therapies should be the ﬁrst line of
treatment. Pharmacotherapy should not be routinely offered to
treat social anxiety disorder in young people and antidepressants
should only offered for moderate to severe depression, in con-
junction with psychological treatments. The relative effectiveness
of psychological and pharmacological treatments for anxiety
disorders in children and young people has been assessed in trials
(RUPP, 2001; POTS, 2004; Beidel et al., 2007; Walkup et al., 2009).
These ﬁndings suggest that CBT, sertraline and their combination
are all possible options for the treatment of these disorders in
childhood. However, uncertainties remain whether: there is an age
below which medication is unsuitable; what the duration of
treatment should be; and the impact of stopping a course of
medication. These concerns, together with parental preference for
psychological over pharmacological interventions for their chil-
dren, are clearly reﬂected in these guidelines. There are no
hypnotics or anxiolytics licensed in the United Kingdom for the
treatment of anxiety in CYP. Hypnotics in CYP are only indicated
for occasional use for night terrors and somnambulism (sleep-
walking) and anxiolytics only to relieve acute anxiety (and related
insomnia) caused by fear (e.g. before surgery) (British National
Formulary Sections 4.1.1 and 4.1.2; British Medical Association and
Royal Pharmaceutical Society of Great Britain, 2014).
This is the ﬁrst study examining trends in the incidence of
recorded: anxiety diagnoses, anxiety symptoms, mixed anxiety
and depression, panic attacks/panic disorder and the use of
hypnotics and anxiolytics in CYP in primary care using routinely
collected data.
2. Aims
The aim of this study is to examine trends in the incidence of
anxiety diagnoses and symptoms, recording of mixed anxiety and
depression, panic attacks/panic disorder, hypnotic and anxiolytic
prescriptions in CYP in primary care.
3. Method
3.1. Design
A retrospective electronic cohort study was conducted utilising
the Secure Anonymised Information Linkage System (SAIL data-
bank; www.saildatabank.com) developed in the Health Informa-
tion Research Unit (HIRU) at the College of Medicine, Swansea
University.
3.2. Ethical approval
Approval was granted from the HIRU Information Governance
Review Panel (IGRP), an independent body consisting of a range of
government, regulatory and professional agencies, which overseas
study approvals in line with permissions already granted to the
analysis of data in the SAIL databank (Lyons et al., 2009; Ford et al.,
2009). We plan to follow the key points of the MRC/Wellcome
Trust data sharing policy
3.3. Data source
The Secure Anonymised Data Linkage (SAIL) databank is an
expanding data repository (over 2 billion records) of anonymised
person based linkable data to support research. SAIL was estab-
lished by the HIRU at Swansea University in 2004 and forms part
of the Health e-Research Collaboration UK (HeRC UK), led by the
Medical Research Council (MRC) and based in the Centre for the
Improvement of Population Health through e-Records Research
(CIPHER). CIPHER is a UK Clinical Research Collaboration (UKCRC)
Public Health Research Centre of Excellence set within the Farr
Institute at the College of Medicine at Swansea University. Policies,
structures and controls are in place to protect patient conﬁdenti-
ality, along with a high performance computing infrastructure and
a reliable matching, anonymisation and encryption process, which
is achieved in conjunction the NHSWales Informatics Service. Data
are imported into SAIL via a split ﬁle approach, whereby demo-
graphic and clinical data are separated at source later to be re-
joined fully encrypted with an allocation of a unique identiﬁer.
This split ﬁle method ensures anonymisation and conﬁdentiality,
whilst maintaining the facility of data linkage at the level of the
individual to any of the datasets housed in SAIL (Lyons et al., 2009;
Ford et al., 2009). This allows data from sources including general
practice records, hospital admissions and demographic informa-
tion to be linked at patient level whilst maintaining anonymity.
In this study data were utilised from: NHS Administrative
Register (NHS AR) a register of all individuals registered with a
Welsh General Practitioner or who have ever had contact with the
NHS; General Practice Database (GPD) attendance and clinical
information for all general practice interactions including symp-
toms, investigations, diagnoses and prescribed medication. Indivi-
dual practices sign up, currently there are 195 practices (out of 474
in Wales) covering a population of over 1.9 million which contains
regularly updated data; Welsh Index of Multiple Deprivation
assigns all Lower Super Output Areas in Wales a deprivation score.
This score is derived from eight separate domains of deprivation
including income, employment and education.
The SAIL databank was interrogated using structured query
language (SQL).
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3.4. Study population and setting
Individuals aged from 6 to 18 years between 1st of January
2003 and 31st December 2011 were identiﬁed. Data collection
began either six months from GP registration or at the study onset
whichever was the later to exclude the risk of retrospective
recording. Data collection ended at the end of registration with a
SAIL supplying GP, date of death, 19th birthday or the study end
whichever was the sooner. Individuals supplying a minimum of six
months of data based on these criteria (and therefore registered
with a SAIL supplying GP for a minimum of one year) were
included in the cohort. Each individual could supply more than
one period of data provided the above criterion were met. For each
year, data were collected between the start and end dates
identiﬁed when constructing the original cohort or, between the
1st of January and the 31st of December if an individual's period of
data collection spanned beyond these dates.
3.5. Measures
Demographic information (age, gender, lower super output
area based deprivation quintile using the Welsh Index of Multiple
Deprivation) were collected. Age and residential information for
each individual was collected based upon the onset of data
collection for each year. Age was described according to categories
of 6–10, 11–14 and 15–18 years in accordance with other studies of
this type (Wijaars et al., 2012) except where numbers were small
when 6–14 and 15–18 age ranges were used.
Other measures were taken from GP computer records using
primary care Read codes. The Read codes and algorithms being
used to identify a new episode of symptoms/diagnoses of anx-
iety have been developed and utilised in previous research
(Supplementary Table 1) (Walters et al., 2012; John et al., 2015).
These included GP recording of i) diagnoses of anxiety e.g. chronic
anxiety, generalised anxiety disorder, anxiety state, ii) anxiety
symptoms e.g. anxiousness, iii) mixed anxiety and depression, iv)
panic attacks and panic disorders. We included emotional dis-
orders with an onset usually in childhood but excluded codes for
phobias, obsessive compulsive disorders, post-traumatic stress
disorder, behavioural disorders, hyperkinetic disorders, conduct
disorders and disorders of social functioning in keeping with other
studies(Rait et al., 2009; Wijaars et al., 2012; Walters et al., 2012).
We excluded adjustment disorders as conceptually they are an
intermediate health condition between normal responses to stress
and more severe emotional disorders such as anxiety and depres-
sion (Casey and Doherty, 2012). Annual prevalence of each subtype
was measured. An annual prevalent case was deﬁned as an
individual with any record of a given subtype in a target year
(Frisher et al., 2004). Cohorts for each year were interrogated to
identify individuals with new (incident) diagnosis/symptoms of
anxiety, mixed anxiety and depression and panic disorder/panic
attacks deﬁned as no record of a given subtype in the previous 12
months. Participants may have more than one episode recorded
for each subtype as long a period of at least 12 months exists
between entries in keeping with previous studies of this type (Rait
et al., 2009; Wijaars et al., 2012; Walters et al., 2012). Data were
also collected on incident anxiolytic and hypnotic prescriptions by
BNF (British Medical Association and Royal Pharmaceutical Society
of Great Britain, 2014) categories (Sections 4.1.1 and 4.1.2) exclud-
ing barbiturates (Section 4.1.3) and antihistamines (Section 3.4.1)
(Supplementary Table 2).
Routine data does not explicitly link medication prescription
with diagnosis. Individuals with an anxiolytic prescription were
further analysed in an attempt to identify the indication for which
the medication was prescribed. Routinely collected electronic GP
data records were reviewed for 6 months either side of the initial
prescription date for depression and anxiety diagnosis and symp-
toms before searching for other possible indications (Gardarsdottir
et al., 2007). These were: pain, enuresis, attention deﬁcit hyper-
activity disorder, conduct disorders, autism, headaches, migraine
prophylaxis sleep problems, other codes of interest (including
tearfulness and psychosis), irritable bowel syndrome, stress, pho-
bias and obsessive disorders, dissociative disorders and eating
disorders. If an individual prescribed relevant anxiolytic/hypnotic
medication had anxiety or depression diagnoses/symptoms recor-
ded then it was assumed that this medication was prescribed for
this indication and no other indications were examined.
3.6. Statistical analysis
Annual incidence rates were calculated using person years at risk
(PYAR) as a denominator. For example a person who supplied six
months of data to the study would contribute 0.5 years to the
denominator. Poisson regression was undertaken to investigate the
adjusted associations between incidence of recorded anxiety symp-
toms/diagnoses, mixed anxiety depression, panic attack/panic disor-
der, hypnotic and anxiolytic prescription on the one hand and, year of
diagnosis, gender, age group and deprivation on the other. Annual
prevalence rates were also calculated utilising PYAR as a denominator.
This is a more appropriate unit rather than number of registered cases
because each individual's duration of follow-up is not ﬁxed (Frisher
et al., 2004).The signiﬁcance of variables in the Poisson regression
modelling was assessed using Wald tests. Robust standard errors for
the estimated incidence rate ratios (IRRs) were utilised to account for
clustering within practices. Analysis was conducted using SPSS
version 20 for Windows.
4. Results
4.1. Sample characteristics
There were 311,343 registered GP patients aged 6–18 years
between 1st January 2003 and 31st December 2011 in the SAIL
databank providing a total of 1,546,489 person years of follow up. The
mean follow-up time was 5.0 years. Annual prevalence of all anxiety
subtypes and anxiolytic and hypnotic prescriptions during the study
period are shown in Supplementary Tables 1 and 2 respectively. There
has been a signiﬁcant increase in prevalence in all subtype diagnoses
and symptoms except mixed anxiety and depression. The prevalence
of anxiety diagnosis increased from 1.97 cases per 1000 person years
at risk (95% conﬁdence interval CI 1.77–2.20) in 2003 to 2.53 (95% CI
2.28–2.79) in 2011 of 6–18 year olds. The prevalence of anxiolytic
prescriptions was 1.90 cases per 1000 person years at risk (95% CI
1.70–2.12) in 2003 and 2.66 (95% CI 2.41–2.93) in 2011. During the
study period there were 3297 new anxiety diagnoses (3151 indivi-
duals), and 1435 incident recordings of anxiety symptoms (1384 indi-
viduals) and 1093 new cases of mixed anxiety and depression (1076
individuals) (Table 1). A total of 2492 individuals received 2638 incid-
ent anxiolytic prescriptions and 1680 individuals received 1730
incident hypnotic prescriptions (Table 2). Only 227 individuals
received incident prescriptions for both anxiolytics and hypnotics.
For all subtypes the majority of records represent incident as opposed
to prevalent cases (Fig. 1).
Adjusted incident rate ratios for year, gender, age group and
deprivation for anxiety diagnosis, anxiety symptoms, panic attack/
panic disorder and mixed anxiety and depression are shown in
Table 1 and for hypnotic and anxiolytic prescriptions in Table 2.
All incident anxiety subtypes increased with age and were nearly
twice as likely in females (panic attack/panic disorder IRR 2.64,
95% CI 2.38–2.93; anxiety diagnosis IRR 1.88, 95% CI 1.75–2.02;
anxiety symptoms IRR 1.84, 95% CI 1.66–2.04) and mixed anxiety
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depression three times as likely (IRR 2.92, 95% CI 2.59–3.28) than
in males (Table 2). For all anxiety subtypes the gender difference
increased with age. The female: male ratio in the 6–14 years age
group compared to the 15–18 year age group is 1.47:1 to 2.16:1 for
anxiety diagnosis, 1.37:1 to 2.14:1 for anxiety symptoms, 1.80:1 to
3.09:1 for mixed anxiety and depression, and 2.33:1 to 2.83:1 for
panic attack/panic disorder. Anxiolytic prescription rates were
signiﬁcantly higher for females (IRR 1.54, 95% CI 1.42–1.68) as
were hypnotic prescription rates (IRR 1.54, 95% CI 1.42–1.68).
The most deprived areas were at higher risk of all subtypes
compared with the least deprived areas (panic attack/panic dis-
orders IRR 1.40 95% 1.21–1.63; anxiety diagnosis IRR 1.33, 95% CI
1.20–1.47; anxiety symptoms IRR 1.42, 95% CI 1.20–1.67; mixed
anxiety depression IRR 2.09, 95% CI 1.79–2.44). Children from the
most deprived quintile were more likely to be diagnosed with
anxiety compared to those in the least deprived quintile between
the ages of 15–18 years (IRR 1.37, 95% CI 1.21–1.56) but not
between the ages of 6 and 14 years (IRR 1.23, 95% CI 0.96–1.59).
This analysis was not performed for symptoms or prescriptions
due to small numbers.
4.2. Trends over time-anxiety
Trends over time of anxiety diagnoses, anxiety symptoms,
panic attack/panic disorder and anxiolytic mixed anxiety and
depression are shown in Fig. 2. A small non-signiﬁcant increase
in the incidence of anxiety diagnoses is apparent from 1.82 cases
per 1000 PYAR in 2003 to 2.37 cases in 2011 (IRR¼1.20, 95% CI
1.02–1.41). The incidence of anxiety symptoms more than tripled
from 0.39 cases per 1000 PYAR in 2003 to 1.50 cases per 1000
PYAR in 2011 (IRR¼3.55, 95% CI 2.65–4.77). In contrast incidence
of mixed anxiety and depression fell from 0.87 to 0.67 cases per
1000 person years over the study period (IRR¼0.68, 95% CI 0.54–
0.86). Incidence of panic attack/panic disorder increased from 0.73
Table 1
Incidence rate ratios (IRR) for anxiety diagnosis, anxiety symptoms, panic attack/panic disorder and mixed anxiety and depression.
Variable Anxiety diagnosis Anxiety symptoms Panic attack/Panic disorder Mixed anxiety depression
Events IRR(95%CI)a Events IRR(95%CI)a Events IRR(95%CI)a Events IRR(95%CI)a
Gender Male 1186 Reference (Pb o0.0001) 523 Reference (Pb o0.0001) 457 Reference (Pb o0.0001) 289 Reference (Pb o0.0001)
Female 2111 1.88(1.75–2.02) 912 1.84(1.66–2.04) 1142 2.64(2.38–2.93) 804 2.92(2.59–3.28)
Age group 6–10 754 0.45(0.4–0.52) 308 0.44(0.36–0.53) 413 0.29(0.24–0.35) 84 0.09(0.04–0.19)
11–14 389 (Pb o0.0001) 153 Reference (Pb o0.0001) 138 Reference (Pb o0.0001) 8 Reference (Pb o0.0001)
15–18 2154 3.18(2.95–3.43) 974 3.47(3.05–3.96) 1048 2.82(2.54–3.12) 1001 13.74(10.95–17.24)
Deprivationc 1 596 (Pb o0.0001) 219 Reference (Pb o0.0001) 265 Reference (Pb o0.0001) 152 Reference (Pb o0.0001)
2 539 1.04(0.92–1.18) 274 1.44(1.21–1.71) 265 1.15(0.98–1.36) 130 0.99(0.83–1.18)
3 735 1.15(1.04–1.27) 340 1.46(1.22–1.74) 361 1.27(1.1–1.47) 221 1.34(1.13–1.59)
4 614 1.09(0.98–1.22) 281 1.37(1.14–1.65) 326 1.31(1.12–1.52) 259 1.8(1.51–2.14)
5 812 1.33(1.2–1.47) 319 1.42(1.2–1.67) 382 1.4(1.21–1.63) 326 2.09(1.79–2.44)
Year 2003 306 Reference (Pb ¼0.120) 65 Reference (Pb o0.0001) 123 Reference (Pb o0.0001) 146 Reference (Pb o0.0001)
2004 366 1.05(0.91–1.22) 130 1.74(1.27–2.37) 179 1.28(1.07–1.53) 163 0.93(0.73–1.19)
2005 361 1.02(0.89–1.16) 134 1.78(1.33–2.38) 188 1.32(1.12–1.56) 141 0.8(0.67–0.95)
2006 371 1.05(0.91–1.21) 154 2.04(1.5–2.77) 177 1.24(1.04–1.49) 112 0.63(0.5–0.8)
2007 411 1.17(1.02–1.33) 169 2.25(1.67–3.02) 210 1.48(1.27–1.73) 107 0.6(0.49–0.73)
2008 358 1.02(0.88–1.18) 166 2.21(1.64–2.99) 179 1.27(1.07–1.51) 107 0.6(0.51–0.71)
2009 386 1.11(0.99–1.25) 183 2.46(1.82–3.33) 204 1.47(1.23–1.74) 107 0.61(0.51–0.73)
2010 376 1.13(0.99–1.28) 205 2.88(2.17–3.82) 172 1.28(1.02–1.62) 107 0.64(0.49–0.84)
2011 362 1.2(1.02–1.41) 229 3.55(2.65–4.77) 167 1.38(1.11–1.72) 103 0.68(0.54–0.86)
a Adjusted for calendar year, gender, age and deprivation.
b based on Wald test.
c Deprivation: 1¼ least deprived; 5¼most deprived.
Table 2
Incidence rate ratios (IRR) for hypnotic and anxiolytic prescriptions.
Variable Hypnotics Anxiolytics
events IRR(95%CI)a events IRR(95%CI)a
Gender Male 674 Reference (pb ¼0.323) 1073 Reference (Pb o0.0001)
Female 1056 1.65(1.5–1.82) 1565 1.54(1.42–1.68)
Age group 6–10 154 0.46(0.33–0.65) 538 0.35(0.3–0.41)
11–14 81 Reference (Pb o0.0001) 213 Reference (Pb o0.0001)
15–18 1495 10.82(8.94–13.11) 1887 3.89(3.52–4.3)
Deprivationc 1 278 Reference (Pb o0.0001) 440 Reference (Pb o0.0001)
2 296 1.23(1.04–1.45) 463 1.21(1.06–1.39)
3 335 1.12(0.95–1.32) 609 1.29(1.15–1.45)
4 365 1.39(1.18–1.63) 548 1.32(1.16–1.5)
5 453 1.59(1.36–1.85) 576 1.28(1.11–1.46)
Year 2003 172 Reference (Pb o0.0001) 214 Reference (Pb¼0.014)
2004 213 1.05(0.85–1.30) 286 1.17(0.95–1.43)
2005 188 0.9(0.73–1.10) 278 1.11(0.91–1.36)
2006 185 0.89(0.71–1.10) 305 1.22(1–1.48)
2007 187 0.9(0.73–1.11) 315 1.27(1.03–1.55)
2008 197 0.95(0.78–1.15) 311 1.25(1.02–1.53)
2009 207 1.01(0.82–1.24) 331 1.35(1.12–1.63)
2010 212 1.07(0.88–1.32) 297 1.26(1.05–1.52)
2011 169 0.95(0.74–1.21) 301 1.41(1.17–1.71)
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to 1.09 cases per 1000 person years from 2003 to 2011 (IRR¼1.38,
95% CI 1.11–1.72).
An initial increasing trend in incident anxiolytic prescriptions is
evident up until 2007 however very little change is seen after this
point resulting in a non-signiﬁcant increase over the study period
from 1.27 to 1.97 cases per 1000 person years (IRR¼1.41, 95% CI
1.17–1.71). While anxiolytic prescriptions for the cohort as a whole
did not change signiﬁcantly over time, there was a signiﬁcant
increase in prescriptions for 15–18 year age group (Fig. 3) from
3.00 to 4.91 cases per 1000 person years (IRR¼1.62, 95% CI 1.30–
2.02). The majority of new anxiolytic prescriptions were for
diazepam which made up around three quarters of new prescrip-
tions over all. This was followed by hydroxyzine hydrochloride.
Incidence of new diazepam prescriptions increased from 0.93
cases per 1000 PYAR in 2003 to 1.40 cases per 1000 PYAR in
2011. Incidence of new prescriptions of hydroxyzine hydrochloride
increased from 0.25 to 0.43 cases per 1000 PYAR during the study
period. Where incident cases had 1 year or more GP follow-up
data (n¼2386) 942 received two or more prescriptions (39%; 95%
CI 38–41) and 340 received ﬁve or more prescriptions (14%; 95% CI
13–16). Of those receiving multiple prescriptions 559 were given
their second prescription within six months of the initial prescrip-
tion date (59%; 95% CI 56–62).
Incident hypnotic prescriptions remain relatively stable over time
with an overall non-signiﬁcant decrease from 1.02 to 0.84 cases per
1000 PYAR (IRR¼0.95, 95%CI 0.74–1.21). Of the 1730 incident
prescriptions only 235 were made for those aged 6–14. The low
rates of prescriptions each year mean that analysis of trends over
time for this younger age group was not meaningful. In contrast to
anxiolytic prescriptions there was a small non-signiﬁcant decrease
from 3.28 to 3.08 cases per 1000 PYAR over time for those aged 15–
18 (IRR¼0.95, 95% CI 0.72–1.24). The most frequently prescribed
hypnotic medication was zopiclone making up just over half of new
prescriptions. This was followed by temazepam. Of those where at
least one year of follow-up data was available following prescription
(n¼1541) 621 received two or more prescriptions (40%; 95% CI 38–
43) and 215 received ﬁve or more prescriptions (14%; 95% CI 12–16).
Of those who received at least one additional prescription 378 were
given their second prescription within six months (61%; 95% CI 57–
65).
Indications associated with incident anxiolytic and hypnotic
medications are shown in Fig. 4. The most commonly associated
indication was pain. Incidence of prescriptions associated with
pain increased from 0.42 to 0.67 cases per 1000 PYAR from 2003 to
2011. Incidence of prescriptions associated with anxiety also
increased from 0.21 in 2003 to 0.37 in 2011 cases per 1000 PYAR.
The only other indication which reached sufﬁcient numbers to be
analysed separately was sleep problems with an incidence of 0.18
cases per 1000 PYAR in 2003 and 0.22 in 2011. Incident prescrip-
tions associated with other indications remained at a low level
throughout the study period with 0.13 cases per 1000 PYAR in
2003 and 0.17 cases per 1000 person years at risk in 2011.
Incidence of prescriptions for which no indication could be found
ﬂuctuated throughout the study period beginning at 1.01 cases per
1000 person years in 2003 decreasing to 0.86 in 2005 before
climbing back up to 1.06 cases in 2011.
5. Discussion
5.1. Main ﬁndings
Since 2003 the incidence of anxiety symptoms in CYP recorded
in primary care has more than tripled, with a comparatively stable
trend in anxiety diagnoses over time. New prescriptions for
anxiolytics have remained at a stable rate for those aged 6–14;
however, new prescriptions have signiﬁcantly increased over time
for those aged 15–18 years. This trend is not reﬂected with
hypnotic prescriptions which show a comparatively stable trend
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over time. Where data is available it appears that around 40% of
new prescription of hypnotics and anxiolytics are associated with
multiple prescriptions in the subsequent year.
5.2. Strengths and limitations
The main strength of this study is its population based sample size.
There is no clear reason to believe the results would differ for the
entire population of Wales or the entire population of UK children.
The results of the current study reﬂect trends in presentation to
primary care, recognition and treatment by GPs and the way in
which depression and anxiety in children and young people is
recorded in primary care. However this is likely to be an under-
estimate of incidence in the community as routine data does not
capture individuals who do not present to their GP or, with whom
depression or anxiety is discussed, but not recorded. This is
common feature of all routinely collected database studies and
results are not intended as an estimate of time trends of the
population as a whole. An additional limitation of utilising routine
data is that the indication for which a medication is prescribed is
not speciﬁcally recorded and can only be inferred based on other
diagnoses around the time of prescription. While work examining
the indications for which a prescription is made in this study is a
good indication of trends over time, the number of individuals for
which no indication is recorded is likely to be inﬂated. This is due
to the nature of the current cohort and the possibility that not all
individuals were registered with SAIL supplying GP at the time
when a diagnosis was recorded. Further work is needed to fully
elucidate the diagnoses which may be linked to this increase in
prescribing.
A further limitation is the lack of information regarding
whether and what interventions have been received at secondary
and tertiary mental healthcare levels for children and adolescents
who are prescribed hypnotics and anxiolytics. In the United
Kingdom, general practitioners are frequently requested to pro-
vide prescriptions for patients who are actively followed up by
specialist mental healthcare, where tailored and carefully super-
vised use of anxiolytics/hypnotics may be appropriate. Our ﬁnd-
ings may be inﬂuenced by a cohort effect as the CYP investigated
age through the study period. The large proportion of individuals
compared to events (e.g. 3297 new anxiety diagnoses compared to
3151 individuals) and prescriptions (e.g. 2492 individuals received
2638 incident anxiolytic prescriptions) suggests that this was not a
major effect. We did not explore prescriptions for antidepressants
which may be indicated for these disorders since this has been
done previously (Wijaars et al., 2012).
The read codes, not speciﬁc to children, utilised in this study
have been previously validated against adult survey data (John
et al., 2015). The use of survey data in order to validate read codes
has a distinct advantage over many other data base studies (Rait
et al., 2009; Wijaars et al., 2012; Walters et al., 2012). However it
may not be appropriate to use adult survey data to validate codes
utilised for CYP. Further research is needed to examine whether
GPs employ the same coding for both adults and young people.
5.3. What this study adds
There has been considerable debate in the literature regarding an
increasing tendency in primary care to diagnose depression and
anxiety in patients presenting with sadness or distress and to offer
them antidepressant or anxiolytic medication (Dowrick and Frances,
2013), in relation to pathologising normal human experience (Watts,
2012). This is of particular concern in CYP (Gaughwin, 2014) where
such presentations, particularly if they are not persistent may reﬂect
‘normal’ processes. Psychotropic prescriptions for CYP are continuing
to rise across western cultures (Olfson et al., 2002; Steinhausen and
Bisgaard, 2014; Middleton et al., 2001; Rani et al., 2008). This is the
ﬁrst study to examine the way in which anxiety problems are
recognised and recorded and to assess prescribing of hypnotics and
anxiolytics in primary care for CYP. The persistence of mental health
issues into adulthood (Costello et al., 2006) and associated adverse
life outcomes (Patel et al., 2007) make recognition and proper
treatment of anxiety and other mental health issues in this group
important in terms of future life outcomes for the individual and
future demands on services. Further research is needed to fully
understand the dramatic increase in symptoms of anxiety.
These results may reﬂect a genuine increase in anxiety in the
young population, increased awareness on the part of GPs or
increased help-seeking behaviour on the part of children and
young people. The increase in anxiolytic prescriptions in 15–18
year olds over the study period is not in keeping with NICE
guidelines for both generalised anxiety disorder in adults (NICE,
2011) and social anxiety disorder in children and young people
(NICE, 2013). NICE recommends that SSRIs are the ﬁrst line
pharmacotherapy for treating adults with generalised anxiety
disorder (NICE, 2011). It may be that the increase in anxiolytic
prescriptions is partially attributable to the controversy surround-
ing SSRI use in adolescents (Committee of Safety of Medicines,
2003) resulting in GPs perceiving anxiolytic medication as a safer
or more acceptable alternative. However it is not possible to draw
this conclusion based on the data available and more research is
required to fully understand the reasons for this increase.
A recent review of the assessment and management of anxiety
disorders in CYP highlights that much is still unknown regarding
the safety of anxiolytic medication, particularly with regards to
benzodiazepines and longer term treatment, in this age group and
further emphasises psychological interventions as a ﬁrst line
treatment (Creswell et al., 2014). In particular trials of benzodia-
zepines in children and young people with anxiety have yielded
mixed results with improvements in anxiety, depression, psycho-
motor excitation, and hyperactivity, but combined with increased
sedation, activation, headache, and nausea (Simeon and Ferguson,
1987). Other trials have found no statistically signiﬁcant differ-
ences to placebo and concerns remain over disinhibition in
children and long term tolerance (Simeon et al., 1992). Thus
whatever the underlying cause, the increase in anxiolytic pre-
scriptions demonstrated in this study is of concern. There is a need
for further research into the safety of these medications, and for
speciﬁc guidance for treating anxiety disorders in CYP.
A recent study from The Health Improvement Network (THIN)
databank has found that recording of incident anxiety diagnoses in
primary care has declined over recent years with a concurrent
increase in incident cases of anxiety symptoms in adults (Walters
et al., 2012). Labelling of mixed anxiety and depression was also
found to nearly halve over the study period. Such results are reﬂected
with diagnoses and symptoms of depression. Overall results suggest
that GPs are increasingly using non-speciﬁc symptom terms for
recording common mental disorders for both adults, and CYP. This
decrease in recording of diagnoses may be partially attributable to
increasingly cautious diagnostic behaviour by GPs. However, an
additional factor that may be of inﬂuence is the updated Quality
and Outcomes Framework (QOF; British Medical Association, NHS
Employers, 2006). Financial incentives are given for general practices
that follow guidelines for stepped care for patients with suspected
depression. Studies suggest the QOF provides a disincentive to rec-
ord a diagnosis of depression and GPs report the use of alternative
labels such as ‘low mood’ (Mitchell et al., 2011). The current study
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demonstrates similar diagnostic behaviour for anxiety where QOF
incentives do not exist, so additional factors such as perceived stigma
may also be contributing to this ﬁnding.
5.4. Implications
The increase in symptoms of anxiety and anxiolytic prescriptions
highlight the need for further research and guidance regarding the
recognition and management of anxiety in young people presenting
to primary care. Anxiolytics are not licenced for use in anxiety, depr-
ession or pain in this age group. The increase in new prescriptions of
anxiolytics in 15–18 year olds is at odds with NICE recommendations,
where they exist, which state that pharmacotherapy should not be
routinely offered in the treatment of social anxiety disorder in young
people (NICE, 2013). Furthermore treatment of anxiety in adults with
benzodiazepines, which comprise the majority of anxiolytic medica-
tions, is speciﬁcally discouraged (NICE, 2011). The increase in symp-
toms of anxiety highlight the need for speciﬁc guidelines on how CYP
suffering with anxiety should be assessed and treated, particularly
older adolescents where pharmacotherapy is increasing. This increase
may reﬂect the paucity of resources at the primary care level for
family-based and psychological therapies for CYP who suffer from
emotional disorders, and difﬁculties in accessing specialist care. The
establishment of the Primary Mental Health worker resource avail-
able to general practices through the Mental Health Measure (Welsh
Government, 2010) legislation in Wales may have a positive impact in
providing more resources for non-pharmacological interventions, as
may the provision of schools based counselling (Welsh Government,
2013) in Wales since 2008, thereby reducing the need for anxiolytic
prescription for this group of patients. It would be important to repeat
this study in the future to ascertain the impact of greater resources for
mental healthcare at the primary healthcare level.
Further research is needed to fully understand the indications for
which, hypnotic and anxiolytic medication are being prescribed
particularly given the large proportion of hypnotic and anxiolytic
prescriptions for which no indication can be found. It appears that
prescriptions associated with pain have increased since 2003. Pre-
scriptions for which no indication could be found have also increased
over the study period further highlighting the need for more research
in this area. It may be that GPs record the indication as free text or
assume they will know the indication from the prescription or it may
be GPs are increasingly choosing not to record depression or anxiety
in this group or that medications are being prescribed for indications
beyond those examined here.
Awareness that GP's are increasingly using non-speciﬁc symptom
codes rather than formal diagnoses for both anxiety and depression
is important for future research based on routinely collected data.
While results here provide a measure of GP recording behaviour,
future research may focus on the impact of a diagnosis compared
with recording of symptoms on patient outcomes. This would
provide further information on the impact of adherence to QOF
guidance. The degree of linkage possible utilising the SAIL databank
means that outcomes including educational data and hospital
admissions could be examined. Future studies may aim to explore
whether the way in which a mental health issue is recorded has an
impact on care or outcomes for the patient.
6. Conclusion
Since 2003 the incidence of anxiety symptoms in CYP recorded
in primary care has more than tripled, with a comparatively stable
trend in the incidence of anxiety diagnoses. Anxiolytic prescrip-
tions for 6–14 year olds have not changed signiﬁcantly over time
but have increased signiﬁcantly for 15–18 year olds which is out of
keeping with current prescribing guidelines. These results may
reﬂect a genuine increase in anxiety in CYP, increased awareness
on the part of General Practitioners or increased help-seeking
behaviour. This study highlights the need for speciﬁc guidelines on
how CYP with anxiety should be assessed and managed in primary
care, particularly in older adolescents and for further guidance on
the use of anxiolytics and hypnotics.
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